Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 20;12(1):74.
doi: 10.1186/s13023-017-0626-0.

Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method

Affiliations

Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method

Carolina S G Freitas et al. Orphanet J Rare Dis. .

Abstract

Background: Lymphangioleiomyomatosis (LAM) is included within group 5 of the current PH classification (unclear multifactorial mechanisms). However, data regarding the occurrence of PH in LAM are scarce. The aims of the study were to describe the prevalence and characteristics of PH in a large cohort of LAM patients with different levels of severity, and to evaluate the role of echocardiography and carbon monoxide diffusion capacity (DLCO) as screening methods for PH in LAM.

Methods: One hundred five LAM patients underwent transthoracic echocardiography, pulmonary function tests (PFTs) and 6-min walk test (6MWT). Patients with a suspicion of PH on echocardiography, defined by the presence of estimated systolic pulmonary artery pressure (PAP) over 35 mmHg or PFT showing DLco below 40% of the predicted value, underwent right heart catheterisation to confirm the diagnosis of PH.

Results: Eight patients (7.6%) had PH confirmed on right heart catheterisation, six patients (5.7%) had a pre-capillary pattern and two patients (1.9%) had a post-capillary profile. Only one patient (1%) had mean PAP over 35 mmHg. Patients with PH had lower FEV1 and DLCO in PFTs and greater oxygen desaturation and dyspnea intensity during 6MWT compared with those without PH. In 63% of the patients with confirmed PH, the right heart catheterisation was performed based only on DLCO result.

Conclusions: The prevalence of PH is low in LAM patients. Pulmonary hypertension in LAM is typically mild and significantly associated with pulmonary parenchymal involvement. Carbon monoxide diffusion capacity significantly improved the identification of PH in LAM patients.

Keywords: Echocardiography; Lymphangioleiomyomatosis; Prevalence; Pulmonary hypertension; Right heart catheterisation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient disposition. Definition of abbreviations: 6MWT: six-minute walk test; DLCO: lung diffusing capacity for carbon monoxide; mPAP: mean pulmonary arterial pressure; PAP: pulmonary arterial pressure; PFT: pulmonary function tests; PH: pulmonary hypertension; RHC: right heart catheterisation
Fig. 2
Fig. 2
Comparison of FEV1 and DLCO between PH vs. non-PH groups. Definition of abbreviations: DLCO: lung diffusing capacity for carbon monoxide; FEV1: forced expiratory volume in the first second; PH: pulmonary hypertension. *p < 0.001. Box plots show the quartiles (box limits), the 10th and 90th percentiles (error bars) and the median (line)

Similar articles

Cited by

References

    1. Johnson SR, Cordier JF, Lazor R, Review Panel of the ERS LAM task Force et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35:14–26. doi: 10.1183/09031936.00076209. - DOI - PubMed
    1. McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med. 2012;186:1210–2. doi: 10.1164/rccm.201205-0848OE. - DOI - PMC - PubMed
    1. Travis WD, Brambilla E, Nicholson AG, WHO Panel et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10:1243–60. doi: 10.1097/JTO.0000000000000630. - DOI - PubMed
    1. Ryu JH, Moss J, Beck GJ, NHLBI LAM Registry Group et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173:105–11. doi: 10.1164/rccm.200409-1298OC. - DOI - PMC - PubMed
    1. Baldi BG, Freitas CS, Araujo MS, et al. Clinical course and characterization of lymphangioleiomyomatosis in a Brazilian reference centre. Sarc Vasc Diffuse Lung Dis. 2014;31:129–35. - PubMed

Substances